Drug Trial Radar · NCT06863402
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Last checked: Nov 20, 2026Latest source record: Oct 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Jun 1, 2029
Study completion Jun 1, 2030
Sponsor
- Lead sponsor
- Roswell Park Cancer InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests how well nemtabrutinib in combination with pembrolizumab works in treating patients with Richter transformation, diffuse large B-cell lymphoma subtype (RT-DLBCL). Nemtabrutinib is in a class of medications called kinase inhibitors. It blocks a protein called BTK, which is present on B-cells (a type of white blood cell) in cancers such as Richter transformation at abnormal levels. This may help keep cancer cells from growing and spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells to grow and spread. Giving nemtabrutinib in combination with pembrolizumab may kill more cancer cells in patients with RT-DLBCL.
Conditions
- Richter Syndrome
- Diffuse Large B-Cell Lymphoma
- Chronic Lymphocytic Leukemia
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone Marrow BiopsyProcedure
Undergo bone marrow biopsy
Computed TomographyProcedure
Undergo PET/CT or CT
EchocardiographyProcedure
Undergo ECHO
Multigated Acquisition ScanProcedure
Undergo MUGA
NemtabrutinibDrug
Given PO
PembrolizumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
Questionnaire AdministrationOther
Ancillary studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall response rateTime frame: After 6 cycles (approximately 18 weeks) (1 cycle = 21 days)
- Quality of lifeTime frame: Up to 3 years after completion of study treatment
- Quality of life -PRO CTCAETime frame: Up to 3 years after completion of study treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Roswell Park Cancer Institute
Buffalo, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.